These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25423093)

  • 41. Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma.
    Brookman-Amissah S; Kendel F; Spivak I; Pflanz S; Roigas J; Klotz T; May M
    BJU Int; 2009 May; 103(10):1375-80. PubMed ID: 19040527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Time to recurrence after nephrectomy as a predictor of cancer-specific survival in localized clear-cell renal cell carcinoma.
    Rodriguez-Covarrubias F; Gomez-Alvarado MO; Sotomayor M; Castillejos-Molina R; Mendez-Probst CE; Gabilondo F; Feria-Bernal G
    Urol Int; 2011; 86(1):47-52. PubMed ID: 20814191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes.
    Parekh DJ; Cookson MS; Chapman W; Harrell F; Wells N; Chang SS; Smith JA
    J Urol; 2005 Jun; 173(6):1897-902. PubMed ID: 15879771
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pre-operative risk stratification for cancer-specific survival in patients with renal cell carcinoma with venous involvement who underwent nephrectomy.
    Nakayama T; Saito K; Fujii Y; Abe-Suzuki S; Nakanishi Y; Kijima T; Yoshida S; Ishioka J; Matsuoka Y; Numao N; Koga F; Kihara K
    Jpn J Clin Oncol; 2014 Aug; 44(8):756-61. PubMed ID: 24872404
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis.
    Fu Q; Chang Y; An H; Fu H; Zhu Y; Xu L; Zhang W; Xu J
    Br J Cancer; 2015 Dec; 113(11):1581-9. PubMed ID: 26554658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Partial nephrectomy versus radical nephrectomy for non-metastatic pathological T3a renal cell carcinoma: a multi-institutional comparative analysis.
    Oh JJ; Byun SS; Lee SE; Hong SK; Lee ES; Kim HH; Kwak C; Ku JH; Jeong CW; Kim YJ; Kang SH; Hong SH
    Int J Urol; 2014 Apr; 21(4):352-7. PubMed ID: 24118633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes following partial nephrectomy by tumor size.
    Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
    J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.
    Harada K; Miyake H; Kusuda Y; Fujisawa M
    BJU Int; 2012 Dec; 110(11 Pt C):E1131-7. PubMed ID: 22712620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study.
    Cindolo L; Chiodini P; Brookman-May S; De Cobelli O; May M; Squillacciotti S; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Wirth MP; Dalpiaz O; Chromecki TF; Shariat SF; Sanchez-Chapado M; Santiago Martin Mdel C; Rocco B; Salzano L; Lotrecchiano G; Berardinelli F; Schips L
    BJU Int; 2013 Sep; 112(5):578-84. PubMed ID: 23470199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Laparoscopic versus open partial nephrectomy for the treatment of pathological T1N0M0 renal cell carcinoma: a 5-year survival rate.
    Permpongkosol S; Bagga HS; Romero FR; Sroka M; Jarrett TW; Kavoussi LR
    J Urol; 2006 Nov; 176(5):1984-8; discussion 1988-9. PubMed ID: 17070227
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.
    Eggener SE; Yossepowitch O; Pettus JA; Snyder ME; Motzer RJ; Russo P
    J Clin Oncol; 2006 Jul; 24(19):3101-6. PubMed ID: 16809736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model.
    May M; Ficarra V; Shariat SF; Zigeuner R; Chromecki T; Cindolo L; Burger M; Gunia S; Feciche B; Wenzl V; Aziz A; Chun F; Becker A; Pahernik S; Simeone C; Longo N; Zucchi A; Antonelli A; Mirone V; Stief C; Novara G; Brookman-May S; ;
    J Urol; 2013 Aug; 190(2):458-63. PubMed ID: 23434943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of UTX expression in patients with clear cell renal cell carcinoma.
    Wang J; Liu L; Xi W; Long Q; Wang Y; Bai Q; Xia Y; Xu J; Guo J
    Urol Oncol; 2016 Aug; 34(8):338.e19-27. PubMed ID: 27106782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of clinicopathological parameters in patients treated for renal cell carcinoma.
    Dall'Oglio MF; Arap MA; Antunes AA; Cury J; Leite KR; Srougi M
    J Urol; 2007 May; 177(5):1687-91. PubMed ID: 17437783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.
    Thompson RH; Leibovich BC; Lohse CM; Cheville JC; Zincke H; Blute ML; Frank I
    J Urol; 2007 Feb; 177(2):477-80. PubMed ID: 17222614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma.
    Chang Y; Xu L; Zhou L; Fu Q; Liu Z; Yang Y; Lin Z; Xu J
    Oncotarget; 2016 Apr; 7(17):24527-36. PubMed ID: 27016418
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.
    Rini B; Goddard A; Knezevic D; Maddala T; Zhou M; Aydin H; Campbell S; Elson P; Koscielny S; Lopatin M; Svedman C; Martini JF; Williams JA; Verkarre V; Radulescu C; Neuzillet Y; Hemmerlé I; Timsit MO; Tsiatis AC; Bonham M; Lebret T; Mejean A; Escudier B
    Lancet Oncol; 2015 Jun; 16(6):676-85. PubMed ID: 25979595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma.
    Wang Z; Xie H; Zhou L; Liu Z; Fu H; Zhu Y; Xu L; Xu J
    Oncotarget; 2016 Aug; 7(32):51525-51534. PubMed ID: 27409666
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients.
    Hupertan V; Roupret M; Poisson JF; Chretien Y; Dufour B; Thiounn N; Mejean A
    Cancer; 2006 Dec; 107(11):2604-8. PubMed ID: 17075871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.